Company Description
BIMI Holdings Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China.
The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies.
It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China.
The company also distributes varieties of products, including raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines.
In addition, it offers prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name.
Further, the company provides medical services in the hospitals, as well as IT research and development services; and operates two private hospitals in China.
It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BIMI International Medical Inc. and changed its name to BIMI Holdings Inc. in January 2024.
BIMI Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.
| Country | China |
| Industry | Pharmaceutical Retailers |
| Sector | Healthcare |
| Employees | 296 |
| CEO | Tiewei Song |
Contact Details
Address: 725 5th Avenue, 15th Floor, 15-01 New York, New York NEW YORK United States | |
| Phone | 212-542-0028 |
| Website | usbimi.com |
Stock Details
| Ticker Symbol | BIMI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001213660 |
| CUSIP Number | 099501108 |
| ISIN Number | US05552Q3011 |
| Employer ID | 02-0563302 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Tiewei Song | Chief Executive Officer and Director |
| Baiqun Zhong | Interim Chief Financial Officer |
| Xiaoping Wang | Chief Operating Officer |
| Fnu Oudom | Chairman of Board and President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 8-K | Current Report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 28, 2024 | 8-K | Current Report |
| Jan 11, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 9, 2024 | 4/A | [Amend] Statement of changes in beneficial ownership of securities |
| Jan 8, 2024 | 8-K | Current Report |
| Jan 5, 2024 | 8-K | Current Report |
| Jan 4, 2024 | 8-K | Current Report |
| Jan 3, 2024 | 8-K | Current Report |
| Dec 19, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |